Warnings and precautions1
Instruct patients to sit or lie down if symptoms develop after dose administration.
Avoid use in patients with pre-existing hypercalcemia and those known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism.
Hypercalciuria and Urolithiasis:
Monitor urine calcium if pre-existing hypercalciuria or active urolithiasis are suspected.
As with all therapeutic proteins, there is potential for immunogenicity. Antibody formation did not appear immune-related hypersensitivity or allergic reactions, or other adverse events.to have any clinically significant impact on safety or efficacy endpoints, including BMD response, fracture reduction,
Reference: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017.